- Ended Q2 with cash and cash equivalents of $90.9M.
- Guides Q3 -$0.30 v -$0.20e, R $43M v $49.1Me
- Guides FY08 -$1.02 v -$1.20 and reflects a change in the timing of approximately $5M in operating expenses, primarily associated with the launch of balsalazide tablet, previously anticipated for 2008 and now anticipated for early 2009.

Other headlines for [SLXP]

• SLXP Yesterday 12:31pm
  Salix Pharmaceuticals Ltd FDA extends review date by three months for Metozol- SLXP says extension has no impact on its previously announced financial guidance for 2008
  
• SLXP Yesterday 11:00am
  Salix Pharmaceuticals Ltd Announces issuance of U.S. Patent for Rifaximin- Provides protection relating to rifaximin for treating irritable bowel syndrome (IBS) caused by small intestinal bacterial overgrowth. - Salix has more...
  
• SLXP 11/5/2008 04:02pm
  Salix Pharmaceuticals Ltd Reports Q3 -$0.11 v -$0.31e, R $42.9M v $43.6Me- Guides FY08 -$0.90 v -$1.05e, R$178-180M v $176.3Me - Cash and cash equivalents were $121.9M on September 30, 2008.
  
• SLXP 10/31/2008 03:53pm
  Salix Pharmaceuticals Ltd APRISO Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis- APRISO is the first and only 5-ASA with Intellicor extended release delivery technology. - The Company more...
  
• SLXP 10/9/2008 01:13pm
  Salix Pharmaceuticals Ltd Block of 1M shares trades at $7.00
  

Healthcare sector headlines

• PRGO Today 01:34pm
  Perrigo Co Hearing Credit Suisse making cautious comments (timing uncertain)
  
• GILD Today 12:50pm
  Gilead Sciences Inc CEO: Expansion in US AIDs market is viewed as a 'significant' opportunity, expects large growth in sales of Hepatitis B drug
  
• THRX Today 12:34pm
  Theravance Inc FDA advisory panel: Telavancin antibiotic is safe and effective; vote is 21-5
  
• AET Today 12:32pm
  Aetna Inc CEO: We are definitely taking market share, growing across all segments
  
• NUVA Today 11:44am
  NuVasive Inc Hearing defended at Piper Jaffray (timing uncertain)